BUFFALO, NY- October 31, 2024 – A new #research paper was #published as the #cover of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 20, entitled, “Longevity biotechnology: bridging AI, biomarkers, geroscience and clinical applications for healthy longevity.”

This paper summarizes recent advances in healthspan biotechnology discussed at the 2023 Aging Research and Drug Discovery Meeting (ARDD), where leading experts reviewed breakthroughs in artificial intelligence (AI), biomarkers, aging clocks, geroscience, and clinical trials that support healthier, longer lives. The authors present a comprehensive view of how these technologies are shaping research and industry approaches to aging, focusing on targeting aging itself to reduce multiple age-related diseases and extend the healthy years of life.

With people living longer, addressing age-related health issues is more critical than ever. Traditional healthcare often treats age-related diseases individually, overlooking aging as a core issue. Longevity biotechnology seeks to change this by combining AI with biomarker analysis to detect early signs of aging, enabling targeted interventions that not only delay disease but also promote longer, healthier lives.

Led by corresponding authors Yu-Xuan Lyu from Southern University of Science and Technology Shenzhen; Alex Zhavoronkov from Insilico Medicine AI Limited, Masdar City, Abu Dhabi; Morten Scheibye-Knudsen and Daniela Bakula from the Center for Healthy Aging, University of Copenhagen, this research synthesizes the potential of AI to identify precise biomarkers of aging, supporting the development of "aging clocks"—tools that use biological data to estimate a person’s biological age and health risks. These tools help clinicians tailor prevention and treatment to individual needs. Additionally, AI speeds up the discovery of drugs that target primary aging drivers, such as cellular damage and decreased cellular energy, offering the potential to slow, prevent, or even reverse certain effects of aging and enhance quality of life.

“The fusion of AI with biomarker research has markedly revolutionized the way biomarkers are identified and validated in the field of ageing.”

This approach not only promises to slow, prevent, or even reverse certain effects of aging but also emphasizes the potential for AI-driven methods to extend healthspans.

In conclusion, the authors emphasize the need for continued investment in AI-driven therapies and biomarker research, which hold the potential to redefine aging care and improve health outcomes as people grow older.

DOI - https://doi.org/10.18632/aging.206135

Corresponding Authors - Yu-Xuan Lyu - [email protected], Alex Zhavoronkov - [email protected], Morten Scheibye-Knudsen - [email protected], and Daniela Bakula - [email protected]

Video short - https://www.youtube.com/watch?v=Hpfe5WJ5g7I

Sign up for free Altmetric alerts about this article -

https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206135

Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts

Keywords - aging, biotechnology, artificial intelligence, healthy longevity

About Aging-US

The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.)

Please visit our website at https://www.Aging-US.com​​ and connect with us:

Facebook - https://www.facebook.com/AgingUS/

X - https://twitter.com/AgingJrnl

Instagram - https://www.instagram.com/agingjrnl/

YouTube - https://www.youtube.com/@AgingJournal

LinkedIn - https://www.linkedin.com/company/aging/

Pinterest - https://www.pinterest.com/AgingUS/

Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc